Functional long-range interactions of the IgH 3′ enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells

Oncogene

Volumn 27, Issue 53, 2008, Pages 6720-6728

  Duan, H ^a,b   Xiang, H ^a,b   Ma, L ^a,b   Boxer, L M ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bcl 2; IgH enhancer; Spatial interactions; t(14; 18) lymphoma

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN HEAVY CHAIN; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 2; PROTEIN BCL 2; SMALL INTERFERING RNA; TRICHOSTATIN A;

ARTICLE; CHROMOSOME 14; CHROMOSOME 18; CHROMOSOME ANALYSIS; CONTROLLED STUDY; ENHANCER REGION; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; ENHANCER ELEMENTS, GENETIC; ENZYME INHIBITORS; GENES, BCL-2; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA; OCTAMER TRANSCRIPTION FACTOR-2; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC;

EID: 56249103761     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.286     Document Type: Article

References (26)

1. Dekker J, Rippe K, Dekker M, Kleckner N. (2002). Capturing chromosome conformation. Science 295: 1306-1311.
2. Desoize B. (1994). Anticancer drug resistance and inhibition of apoptosis. Anticancer Res 14: 2291-2294.
3. Duan H, Heckman CA, Boxer LM. (2005). Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608-1619.
4. Duan H, Heckman CA, Boxer LM. (2007). The immunoglobulin heavy-chain gene 3′ enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells. Oncogene 26: 2635-2641.
5. Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ. (1987). Expression of bcl-2 and bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 80: 1512-1515.
6. Hagege H, Klous P, Braem C, Splinter E, Dekker J, Cathala G et al. (2007). Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nature Protocols 2: 1722-1733.
7. Heckman CA, Cao T, Somsouk L, Duan H, Mehew JW, Zhang C et al. (2003a). Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Res 63: 6666-6673.
8. Heckman CA, Duan H, Garcia PB, Boxer LM. (2006). Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression. Oncogene 25: 888-898.
9. Heckman CA, Mehew JW, Boxer LM. (2002). NF-êB activates bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21: 3898-3908.
10. Heckman CA, Mehew JW, Ying G-G, Introna M, Golay J, Boxer LM. (2000). A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. J Biol Chem 275: 6499-6508.
11. Heckman CA, Wheeler MA, Boxer LM. (2003b). Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene 22: 7891-7899.
12. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336.
13. Ji L, Mochon E, Arcinas M, Boxer LM. (1996). CREB proteins function as positive regulators of the translocated bcl-2 allele in t(14;18) lymphomas. J Biol Chem 271: 22687-22691.
14. Ju Z, Volpi SA, Hassan R, Martinez N, Giannini SL, Gold T et al. (2007). Evidence for physical interaction between the immunoglobulin heavy chain variable region and the 3′ regulatory region. J Biol Chem 282: 35169-35178.
15. Khamlichi AA, Pinaud E, Decourt C, Chauveau C, Cogne M. (2000). The 3′ IgH regulatory region: a complex structure in a search for a function. Adv Immunol 75: 317-345.
16. Liu Z, Garrard WT. (2005). Long-range interactions between three transcriptional enhancers, active Vκ gene promoters, and a 3′ boundary sequence spanning 46 kilobases. Mol Cell Biol 25: 3220-3231.
17. Madisen L, Groudine M. (1994). Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells. Gene Devel 8: 2212-2226.
18. Miele A, Gheldof N, Tabuchi TM, Dostie J, Dekker J. (2006). Mapping chromatin interactions by chromosome conformation capture (3C). In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA et al. (eds). Current Protocols in Molecular Biology. John Wiley & Sons: New York, pp 21.11.1-21.11.20.
19. Mills FC, Harindranath N, Mitchell M, Max EE. (1997). Enhancer complexes located downstream of both human immunoglobulin C-alpha genes. J Exp Med 186: 845-858.
20. Palstra R-J, Tolhuis B, Splinter E, Nijmeijer R, Grosveld F, de Laat W. (2003). The β-globlin nuclear compartment in development and erythroid differentiation. Nat Genet 35: 190-194.
21. Reed JC, Kitada S, Takayama S, Miyashita T. (1994). Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5 (Suppl 1): S61-S65.
22. Schmitt CA, Lowe SW. (2001). Bcl-2 mediates chemoresistance in matched pairs of primary Em-myclymphomas in vivo. Blood Cells Mol Dis 27: 206-216.
23. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P et al. (1988). Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 7: 123-131.
24. Splinter E, Grosveld F, de Laat W. (2004). 3C technology: analyzing the spatial organization of genomic loci in vivo. Methods Enzymol 375: 493-507.
25. Tolhuis B, Palstra R-J, Splinter E, Grosveld F, de Laat W. (2002). Looping and interaction between hypersensitive sites in the active β-globin locus. Mol Cell 10: 1453-1465.
26. Wilson BE, Mochon E, Boxer LM. (1996). Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 16: 5546-5556.